Medication info

Rosuvastatin and Valsartan Film-Coated Tablets 10/160 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Hankook Hytex Pharmaceuticals Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 202003913 · Approved 2020.05.27 · Insurance code 649104900

Summary

Main use
Improvement of (hypertension and heart failure) and treatment of (hypercholesterolemia)
Who takes it
Adults · Children
Adult dose
This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, an oral dose of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is co-administered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, the dose may be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate based on LDL cholesterol levels, treatment goals, and the patient's response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 mg daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Valsartan: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Hankook Hytex Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of (hypertension and heart failure) and treatment of (hypercholesterolemia)

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed type hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypercholesterolemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
View approved original text

This medication is used for patients who need to take both Valsartan and Rosuvastatin. Valsartan is effective for patients with essential hypertension and heart failure who do not respond to ACE inhibitors, and it helps reduce the risk of mortality following myocardial infarction. Rosuvastatin is used for patients with hypercholesterolemia and various types of dyslipidemia, reducing the risk of cardiovascular disease and slowing the progression of atherosclerosis. By combining these two medications, they help control blood pressure and cholesterol simultaneously, improving the patient's cardiovascular health.

How to take

Adult dose

This medicine should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, an oral dose of 80 mg of valsartan once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be co-administered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is co-administered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following weeks, the dose may be increased, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate based on LDL cholesterol levels, treatment goals, and the patient's response, at intervals of 4 weeks or longer, and may be increased to a maximum of 20 mg daily. 2. Elderly patients No dose adjustment is necessary. 3. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer this medicine to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

Essential hypertension: Safety and efficacy have not been established in children and adolescents under 18 years of age. Valsartan: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. It should not be taken if there is an allergy to any components of this medication or to the medication itself. Women who are pregnant or may become pregnant, as well as breastfeeding women should not take this medication, and women of childbearing age should use appropriate contraceptive methods. Patients with severely impaired liver function or specific liver diseases, patients with severely decreased kidney function, and patients with muscle disorders should not take this medication. Elderly patients, patients with high potassium levels, patients with slightly impaired liver function, and patients with heart disease should take special caution when using this medication. This medication may cause muscle-related side effects such as myalgia, muscle weakness, and rarely rhabdomyolysis, so if muscle pain or weakness, accompanied by fever occurs, immediate consultation with a doctor is recommended. Liver function abnormalities may occur, so it is advised to conduct liver function tests before and during treatment with this medication. This medication lowers blood pressure and may cause symptoms of hypotension (dizziness, fainting) at initiation of treatment, and if such symptoms occur, immediate notification to healthcare professionals is required. Drug interactions may occur when taken with specific medications, so current medications must be disclosed to healthcare professionals. This medication has not been proven safe and effective in children and adolescents (under 18 years old). In case of overdose, as there is no specific antidote, immediate medical attention is required for proper treatment, and hypotension or decreased consciousness may occur. During storage, keep it away from children's reach and do not transfer it to another container.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase levels, increased serum creatinine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin neoplasm-like state, shingles, intervertebral disc herniation, hemoptysis, sputum disease, bronchitis, dysesthesia, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, hypertension exacerbation, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, angina exacerbation, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, peripheral neuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, hypotension, decreased consciousness, circulatory collapse, shock, tachycardia, bradycardia, hypoglycemia, angioedema, interstitial pneumonia, syncope, angioneurotic edema, renal impairment, hyperkalemia, orthostatic dizziness, orthostatic hypotension, fatigue, diarrhea, nausea, renal impairment, hyperkalemia, angioedema, erythema, pruritus, serum sickness, vasculitis, arrhythmia, intestinal vascular edema, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased red blood cell volume, decreased hemoglobin

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light to enter. Additionally, it is important to store it at room temperature between 1°C to 30°C to maintain its efficacy.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.